Abstract
A number of medications are approved in the United States (US) for treatment of moderate-to-severe pain. Clinical trial definitions of moderate-to-severe pain in osteoarthritis (OA) are generally based on scoring cut-points for patient-reported pain, physical function, and global assessments. However, in real world settings, categorizing patients as having mild, moderate, or severe OA is not straightforward. The objective of this study was to assess patient-reported OA severity in terms of patient function using the Adelphi Disease Specific Programme for Arthritis (OA DSP VII, 2008).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
